ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2023
May 04 2023 - 6:30AM
ImmuCell Corporation (Nasdaq: ICCC)
(“ImmuCell” or the “Company”), a growing animal health company that
develops, manufactures and markets scientifically proven and
practical products that improve the health and productivity of
dairy and beef cattle, expects to report unaudited financial
results for the quarter ended March 31, 2023 after the market
closes on Thursday, May 11, 2023.
The Company has scheduled a conference call the next morning,
Friday, May 12, 2023, at 9:00 AM ET to review its first quarter
financial results. Interested parties can access the conference
call by dialing (844) 855-9502 (toll free) or (412) 317-5499
(international) at 9:00 AM ET. A teleconference replay of the call
will be available until May 19, 2023 at (877) 344-7529 (toll free)
or (412) 317-0088 (international), utilizing replay access code
#3163870.
The Company expects to file its Quarterly Report on Form 10-Q
after the market closes on Thursday, May 11, 2023. The Company
anticipates no change to the preliminary sales results for the
first quarter of 2023 that were disclosed on April 5, 2023.
Investors are encouraged to review the Company’s updated
Corporate Presentation slide deck that provides an overview of the
Company’s business which can be accessed under the “Investors” tab
of the Company’s website at www.immucell.com, or by request to the
Company, after the market closes on Thursday, May 11, 2023.
About ImmuCell:ImmuCell Corporation's
(Nasdaq: ICCC) purpose is to create scientifically
proven and practical products that improve the health and
productivity of dairy and beef calves. ImmuCell manufactures
and markets First Defense®, providing
Immediate Immunity™ to newborn dairy and beef
calves, and is in the late stages of developing
Re-Tain®, a novel treatment for subclinical
mastitis in dairy cows without a milk discard requirement that
provides an alternative to traditional antibiotics. Press releases
and other information about the Company are available at:
http://www.immucell.com.
Contacts: Michael F. Brigham, President
and CEO
ImmuCell
Corporation
(207)
878-2770
Joe Diaz, Robert Blum and Joe Dorame
Lytham
Partners, LLC
(602)
889-9700
iccc@lythampartners.com
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From Apr 2024 to May 2024
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From May 2023 to May 2024